Form 4: Akebia Therapeutics Director Adrian Adams Acquires Shares and Options

Director Adrian Adams acquired 30,000 shares of common stock and options to purchase 45,000 shares of Akebia Therapeutics, Inc.

Summary

• On June 6, 2024, Adrian Adams, a director of Akebia Therapeutics, Inc., acquired 30,000 shares of common stock and options to purchase 45,000 shares.
• The shares were acquired at a price of $0.00.
• The options have an exercise price of $1.07 and expire on June 6, 2034.
• The restricted stock units (RSUs) and stock options were granted under the company's 2023 Stock Incentive Plan and the Third Amended and Restated Non-Employee Director Compensation Program.
• The RSUs and stock options will vest in full on the first anniversary of the grant date or earlier if the first annual meeting of the Company's stockholders occurs after the grant date, subject to continued service.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it's a standard disclosure of insider transactions. The acquisition of shares and options by a director could be interpreted as a slightly positive signal, but it's not a strong indicator.

Positives

• The acquisition of shares and options by a director could be seen as a positive sign, indicating confidence in the company's future prospects.

Future Outlook

The vesting of the RSUs and stock options is contingent upon the director's continued service to the company.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in the pharmaceutical industry as part of executive compensation packages.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment.

Key Dates